Kennedy to link Tylenol use in pregnancy to autism, report says

U.S. Health Secretary Robert F. Kennedy Jr. reportedly plans to announce a potential link between pregnant women's Tylenol use and autism, a claim that contradicts established medical guidelines and led to a 14% drop in Kenvue (KVUE.N) shares, the manufacturer. This potential announcement, despite a lack of scientific consensus and previous federal court dismissals of similar lawsuits due to insufficient evidence, introduces significant regulatory uncertainty and market volatility for pharmaceutical companies, particularly given the widespread use of acetaminophen and the ongoing scientific debate.

Analysis

The report of a forthcoming announcement from the U.S. Health Secretary linking Tylenol use during pregnancy to autism has introduced significant event risk for Kenvue Inc. (KVUE), precipitating a 14% decline in its shares. This potential government position directly contradicts the current consensus утвержденной U.S. Food and Drug Administration and major medical organizations, which maintain that acetaminophen is safe for use during pregnancy. The market's sharp negative reaction underscores the gravity of regulatory and headline risk, even when the scientific basis is contested. Notably, the claim is challenged by recent large-scale research, including a 2024 JAMA study of 2.4 million children that found no evidence of a causal link, and is described by experts as a rehash of existing, unproven theories. Furthermore, this development re-emerges in a contentious legal environment, following a December 2023 federal court ruling that dismissed hundreds of similar lawsuits due to a lack of scientific evidence, although that ruling is currently under appeal. The situation presents a material overhang for Kenvue, combining political pressure, the threat of renewed litigation, and potential erosion of consumer trust in its flagship Tylenol brand.

Key Decisions for Investors

• Investors in Kenvue should re-evaluate their positions to account for heightened headline and litigation risk, as an official government report ângulo could damage brand equity and spur new lawsuits regardless of its scientific validity.
• Traders and portfolio managers should closely monitor the forthcoming U.S. appeals court hearing نتائج and any final, official report from the Department of Health and Human Services, as these will serve as a primary catalyst for KVUE's stock.
• For contrarian or long-term investors, the disconnect between the reported political stance and the prevailing scientific consensus, including the recent 2.4 million-person JAMA study, may present an opportunity if they believe the market has overreacted to what may ultimately be unsubstantiated claims.